Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: Longitudinal tumor hypoxia imaging with [18F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity

Fig. 3

a Tumor volume changes and b animal weight fluctuations over the study period of 21 days. c Longitudinal tumor FAZA uptake (%ID/g) and d tumor hypoxic fraction calculated from the PET data set. Each data point (except for day 21, transparently masked in gray) represents the mean ± standard deviation obtained from five animals, each bearing bilateral tumors, for a total of 10 tumors per treatment group. Asterisk denotes statistically significant difference (p < 0.05) between the nal-IRI (10 mg/kg) and either one or both the other two treatment groups. e Three sets of representative PET image (left) and CAIX (middle) and EF5 (right) stained tumor sections obtained from three animals, one belonging to each treatment group. Qualitative demonstration that the degree of FAZA-PET signal is confirmed by the level of CAIX and EF5 immunohistochemistry staining (i.e., high FAZA uptake correlates to high CAIX and high EF5 staining)

Back to article page